6-Nitro-chinazolin | 7556-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-Nitro-chinazolin
• 英文别名: 6-nitro-quinazoline；6-Nitroquinazoline
• CAS: 7556-95-8
• 化学式: C₈H₅N₃O₂
• mdl: MFCD18448929
• 分子量: 175.147
• InChiKey: RPTKRGHYKSBDJL-UHFFFAOYSA-N

物化性质

• 熔点：
  174.5-175 °C
• 沸点：
  346.2±15.0 °C(Predicted)
• 密度：
  1.437±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-Nitro-chinazolin 在 盐酸 、 sodium azide 、 titanium(III) chloride 、 sodium acetate 、 sodium nitrite 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 6-azidoquinazoline
  参考文献：
  名称：

  6-叠氮喹啉和6-叠氮二嗪的光解环扩展：一些意想不到的氮杂环庚烷开环反应

  摘要：

  6-叠氮喹啉在MeOH-KOMe-二恶烷中的光解产生8,9-二氢-5,7-二甲氧基-5H-嘧啶并[5,4-]氮杂（5），在酸水解时开环反应成嘧啶-甲醛（ 7）。讨论了这种意外的二甲氧基嘧啶基-氮杂a的形成机理，并与先前涉及6-叠氮基-2,3-二氢呋喃基和6-叠氮基-23-二氢噻吩基-[2,3-b]喹啉的类似结果相关联

  DOI：

  10.1016/s0040-4020(01)89775-1
• 作为产物：
  描述：

  喹唑啉 在 硫酸 、 硝酸 作用下， 生成 6-Nitro-chinazolin
  参考文献：
  名称：

  Predictors and Incidence of Urinary Incontinence in Elderly Canadians With and Without Dementia — A Five-Year Follow Up: The Canadian Study of Health and Aging

  摘要：

  摘要本研究以加拿大全国健康与老龄化研究为基础，旨在确定社会人口和医疗因素、认知和功能状况对尿失禁发生的重要预测作用，并按性别和年龄组估计五年的发病率。对加拿大健康与老龄化研究（Canadian Study of Health and Aging）中于 1992 年接受临床检查并在当时排尿的参与者进行了跟踪调查，并于 1997 年再次确定了他们的尿失禁状况。分别为男性（306 人）和女性（520 人）幸存者建立了以每日尿失禁和每日或少于每日尿失禁为结果的多变量逻辑回归模型。预测变量分为以下几组：社会人口因素、认知状况、功能状况、糖尿病和中风。此外，还估算了按性别和年龄组分列的每日尿失禁和小于每日尿失禁的五年累计发生率。结果表明，女性尿失禁的发生率高于男性，而且随着年龄的增长，男女尿失禁的发生率均有所上升。尤其是在男性中，住在养老院的人比住在社区的人更容易出现尿失禁。尿失禁随痴呆症的严重程度而急剧增加，但随身体活动不便而增加。糖尿病与男性尿失禁的发生有关，但与女性无关。结论是，尿失禁在老年人中很常见，对老年人进行常规医疗和护理评估时应询问是否存在尿失禁。出现尿失禁的老年人通常患有痴呆症且身体机能受损。评估和处理的程度应根据每位患者的具体情况认真制定。

  DOI：

  10.1017/s0714980800000672

文献信息

• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。
• Investigation on the photoreactions of nitrate and nitrite ions with selected azaarenes in water
  作者：Toralf Beitz、Wolfgang Bechmann、Rolf Mitzner

  DOI：10.1016/s0045-6535(98)00188-x

  日期：1999.1

  spectrum of oxidized products corresponded to the one got in the photoreactions of azaarenes with hydrogen peroxide. The formation of several oxidation and nitration products of the pyridine ring with its low electron density was explained by the reaction of excited states of azaarenes. The photoreactions with nitrite ions only led to the formation of oxidized and nitrated products. Nitroso products were not

  在λ= 313 nm的辐射下研究了选定的氮杂芳烃与硝酸根和亚硝酸根离子的光反应。两种阴离子的激发导致几种光化学反应，主要形成羟基自由基和氮氧化物。天然水的净化能力，即无机物和有机物的氧化，是由于羟基的形成。在所研究的光反应的主要产物中发现了氮杂氮杂的硝化异构体。氮氧化物负责产生具有高毒性潜力的硝化衍生物。它们的形成可以通过两种机制的平行发生来解释，即分子机制和自由基机制。随着氮杂芳烃电离势的增加，分子机理变得越来越重要。氧化产物的光谱对应于氮杂芳烃与过氧化氢的光反应所得到的光谱。低电子密度的吡啶环的几种氧化和硝化产物的形成可以通过氮杂芳烃的激发态反应来解释。与亚硝酸根离子的光反应仅导致形成氧化和硝化的产物。亚硝基产物未形成。一氧化氮的反应性对于与氮杂芳烃的反应而言太低。与亚硝酸根离子的光反应仅导致形成氧化和硝化的产物。亚硝基产物未形成。一氧化氮的反应性对于与氮杂芳烃的反应而言太低。与亚硝酸
• Preparation of substituted quinazolines
  申请人：——

  公开号：US20040158065A1

  公开（公告）日：2004-08-12

  Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula 1 are disclosed. Such inhibitors, which include N-[4-(3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, are useful for treating cancer, restenosis, atherosclerosis, endometriosis and psoriasis. The disclosed methods employ protecting schemes to minimize undesirable diacryloylamino-quinazoline side products. 1

  揭示了制备一般化合物1的酪氨酸激酶不可逆抑制剂的方法和材料。这些抑制剂包括N-[4-(3-氯-4-氟苯胺基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺，可用于治疗癌症、再狭窄、动脉粥样硬化、子宫内膜异位症和牛皮癣。揭示的方法采用保护方案以减少不良的双丙烯酰胺基喹唑啉副产物。
• Predictors and Incidence of Urinary Incontinence in Elderly Canadians With and Without Dementia — A Five-Year Follow Up: The Canadian Study of Health and Aging
  作者：Truls Østbye、Steinar Hunskaar、Elizabeth Sykes

  DOI：10.1017/s0714980800000672

  日期：——

  Based on the national Canadian Study of Health and Aging, the objective of this study was to determine the importance of socio-demographic and medical factors, cognitive and functional status as predictors of the development of urinary incontinence, and to estimate five-year incidence by sex and age group. Participants from the Canadian Study of Health and Aging who underwent a clinical examination in 1992 and were continent for urine at the time were followed up and their continence status was again determined in 1997. Multivariate logistic regression models with daily incontinence and daily or less than daily incontinence as the outcomes were developed separately for male (n = 306) and female (n = 520) survivors. Predictor variables were introduced in the following chunks: socio-demographic factors; cognitive status; functional status, diabetes and stroke. Five-year cumulative incidence of daily and less than daily incontinence by sex and age group was also estimated. Results indicated that the incidence of urinary incontinence was higher in women than in men, and increased by age in both men and women. Especially among men, those in institutions were much more likely to develop urinary incontinence than those in the community. Incontinence increased dramatically with severity of dementia, less so with physical immobility. Diabetes mellitus was related to the development incontinence in men but not in women, prior stroke was related to development of incontinence in both sexes. It is concluded that urinary incontinence is common in older persons, and enquiries about its presence should be part of routine medical and nursing assessment of older persons. Those who develop incontinence commonly have dementia and are physically impaired. The extent of assessment and management should be carefully tailored to each individual patient.

  摘要本研究以加拿大全国健康与老龄化研究为基础，旨在确定社会人口和医疗因素、认知和功能状况对尿失禁发生的重要预测作用，并按性别和年龄组估计五年的发病率。对加拿大健康与老龄化研究（Canadian Study of Health and Aging）中于 1992 年接受临床检查并在当时排尿的参与者进行了跟踪调查，并于 1997 年再次确定了他们的尿失禁状况。分别为男性（306 人）和女性（520 人）幸存者建立了以每日尿失禁和每日或少于每日尿失禁为结果的多变量逻辑回归模型。预测变量分为以下几组：社会人口因素、认知状况、功能状况、糖尿病和中风。此外，还估算了按性别和年龄组分列的每日尿失禁和小于每日尿失禁的五年累计发生率。结果表明，女性尿失禁的发生率高于男性，而且随着年龄的增长，男女尿失禁的发生率均有所上升。尤其是在男性中，住在养老院的人比住在社区的人更容易出现尿失禁。尿失禁随痴呆症的严重程度而急剧增加，但随身体活动不便而增加。糖尿病与男性尿失禁的发生有关，但与女性无关。结论是，尿失禁在老年人中很常见，对老年人进行常规医疗和护理评估时应询问是否存在尿失禁。出现尿失禁的老年人通常患有痴呆症且身体机能受损。评估和处理的程度应根据每位患者的具体情况认真制定。
• Substituted quinazoline derivatives
  申请人：American Cyanamid Company

  公开号：EP0787722A1

  公开（公告）日：1997-08-06

  This invention provides a compound having the formula wherein: Xis phenyl which is optionally substituted; R and R1are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl; R2is hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl; Yis a radical selected from the group consisting of R3is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl; n = 2-4; or a pharmaceutically acceptable salt thereof, with the proviso that each R3 of Y may be the same or different which are useful as antineoplastic agents.

  本发明提供了一种化合物，其化学式为：其中：X是苯基，可选地取代；R和R1分别独立地是氢、卤素、烷基、烷氧基、羟基或三氟甲基；R2是氢、烷基、烷氧基、羟基或三氟甲基；Y是从以下组中选择的基团：R3独立地是氢、烷基、羧基、羧烷氧基、苯基或羧基烷基；n = 2-4；或其药学上可接受的盐，其中Y的每个R3可以相同也可以不同，其作为抗肿瘤剂有用。